RxDoctor Payments Data

Kelley Walker

Psychiatry · Knoxville, TNNPI 1730173790

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.7% of the total across 969 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 11.0% — the pattern of someone who eats at a lot of different presentations. Among psychiatry clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$17,064in general payments, 2019–2025

Across 969 payments — averaging $17.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$2K
  • Otsuka America Pharmaceutical, Inc.$2K
  • AbbVie$2K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
  • Alkermes, Inc.$1K
  • Teva Pharmaceuticals USA, Inc.$1K
  • plus $8K from 30 others

What the payments were for

  • Food & beverage$17,018100%
  • Education$470%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,064 in reported general payments places this provider in the 95th percentile of 503 psychiatry providers in Tennessee.

See all psychiatry providers in Tennessee

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate12$89,274
RexultiBrexpiprazole24$49,610
CaplytaLumateperone Tosylate13$21,721
VyvanseLisdexamfetamine Dimesylate46$17,644
Bupropion XlBupropion Hcl164$6,639
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine60$4,020
Methylphenidate ErMethylphenidate Hcl27$3,259
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine95$2,918
Oxcarbazepine45$2,571
Vilazodone Hcl28$2,567
Aripiprazole82$2,490
Lisdexamfetamine Dimesylate14$2,218
Desvenlafaxine Succinate ErDesvenlafaxine Succinate23$2,176
Gabapentin136$2,150
Lamotrigine131$1,983

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$1,878$89,27412 claims
Otsuka America Pharmaceutical, Inc.Rexulti$1,781$49,61024 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$1,360$21,72113 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$208$17,64446 claims
Almatica Pharma LLCSertraline Hcl$81$86494 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 503 psychiatry providers in Tennessee.

Other psychiatry in Knoxville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →